Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methamphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.70 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.70 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methamphetamine SCHEMBL10280466 | 0.98 | SIGMAR1 (0.68) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL28255325 | 0.98 | SIGMAR1 (0.72) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL7156078 | 0.93 | SIGMAR1 (0.75) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL1608168 | 0.86 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL9114797 | 0.86 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Levmetamfetamine SCHEMBL9114800 | 0.86 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL42098 | 0.86 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Levmetamfetamine SCHEMBL42099 | 0.86 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL42100 | 0.86 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL13747483 | 0.84 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590942-A1 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| EP-1926711-B1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| WO-2012006202-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| EP-1867645-B1 | Variolin derivatives and their use as antitumor agents | PHARMA MAR SA (ES) | 2010-09-08 | — | — | EP | disclosed |
| US-7772241-B2 | Variolin derivatives and their use as antitumor agents | PHARMA MAR S.A. (ES) | 2010-08-10 | — | — | US | disclosed |
| US-7713996-B2 | Indolyl derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMA MAR, S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| US-7495000-B2 | Variolin derivatives and their use as antitumor agents | PHARMA MAR, S.A. (ES) | 2009-02-24 | — | — | US | disclosed |
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1867645-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharma Mar, S.A. (ES) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-15 | — | — | US | disclosed |
| EP-1720839-A1 | PYRIDAZINONES AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060235223-A1 | Variolin derivatives and their use as antitumor agents | PHARMA MAR, S.A. (ES) | 2006-10-19 | — | — | US | disclosed |
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | JANSSEN PHARAMACEUTICA, N.V. (BE) | 2005-09-01 | — | — | US | disclosed |
| WO-2005077915-A1 | PYRIDAZINONES AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | SLC6A4 408/4885SIGMAR1 678/4885TAAR1 769/4885 |
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | ITGB4, ITGA4, ITGB5 | SLC6A4 2896/4885SIGMAR1 1580/4885TAAR1 3146/4885 |
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | CBR3, CCNL2, HRH3 | SLC6A4 3224/4885SIGMAR1 164/4885TAAR1 1438/4885 |
| US-20060235223-A1 | Variolin derivatives and their use as antitumor agents | CBR3, CCNL2, HRH3 | SLC6A4 3329/4885SIGMAR1 174/4885TAAR1 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.